The present invention relates to a new process for the production of specific intermediates, which are preferably used in the production of vitamin A and/or vitamin A acetate.

The present invention relates to a new process for the production of specific intermediates, which are preferably used in the production of vitamin A and/or vitamin A acetate.

The present invention provides beta-cryptoxanthin crystals from plant source and a process for its preparation. The present invention particularly relates to a process for the preparation of high purity beta-cryptoxanthin crystals comprising at least about 10% by weight total xanthophylls, of which at least about 75% by weight is trans-beta-cryptoxanthin and the remaining including beta-carotene, and trace amounts of trans-capsanthin and other carotenoids derived from the plant source, including capsicum fruits. The production of beta-cryptoxanthin crystals with high content of trans-beta-cryptoxanthin makes it ideal and suitable for use as a provitamin A source material and also has potential effects on improving bone health and inhibiting bone resorption.

The present invention provides beta-cryptoxanthin crystals from plant source and a process for its preparation. The present invention particularly relates to a process for the preparation of high purity beta-cryptoxanthin crystals comprising at least about 10% by weight total xanthophylls, of which at least about 75% by weight is trans-beta-cryptoxanthin and the remaining including beta-carotene, and trace amounts of trans-capsanthin and other carotenoids derived from the plant source, including capsicum fruits. The production of beta-cryptoxanthin crystals with high content of trans-beta-cryptoxanthin makes it ideal and suitable for use as a provitamin A source material and also has potential effects on improving bone health and inhibiting bone resorption.

The present application relates to processes for the preparation of polyhydroxylated cyclohexyl compounds such as the compounds of Formula I:

##STR00001##

The present invention provides methods and compositions for treating atopic dermatitis by cyclohexenone compounds.

The present invention provides methods and compositions for treating atopic dermatitis by cyclohexenone compounds.

A formulation includes an active agent, a thickening/solidifying agent, and an antioxidant. The active agent is 9-cis-β-carotene (9CBC) or a derivative thereof of the following formula: ##STR00001##
where R.sub.2 is H or methyl; X is ##STR00002##
optionally substituted with one or more methyl groups; n is an integer of 0-16; and the asterisk represents the point of attachment to the cyclohexene ring.

A formulation includes an active agent, a thickening/solidifying agent, and an antioxidant. The active agent is 9-cis-β-carotene (9CBC) or a derivative thereof of the following formula: ##STR00001##
where R.sub.2 is H or methyl; X is ##STR00002##
optionally substituted with one or more methyl groups; n is an integer of 0-16; and the asterisk represents the point of attachment to the cyclohexene ring.

A formulation includes an active agent, a thickening/solidifying agent, and an antioxidant. The active agent is 9-cis-β-carotene (9CBC) or a derivative thereof of the following formula:

##STR00001##

where R.sub.2 is H or methyl; X is

##STR00002##

optionally substituted with one or more methyl groups; n is an integer of 0-16; and the asterisk represents the point of attachment to the cyclohexene ring.